Intermediate for Carfilzomib. Carfilzomib (trade name: Kyprolis) is an anti-cancer drug acting as a selective proteasome inhibitor. Carfilzomib has been approved by the U.S Food and Drug Administration on July 20, 2012.
Product Name: (S)-Benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate
CAS Number: 70637-26-2
Molecular Weight:  468.5918
Molecular Formula:  C27H36N2O5
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.